Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 6/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4307781 | 0.99 | PTGDR2 (0.41) | PTGDR2MAPTTHRBSRCMTNR1A | |
| SCHEMBL4310845 | 0.95 | MAPT (0.39) | PTGDR2MAPTTHRBSRC | |
| SCHEMBL4308723 | 0.94 | PTGDR2 (0.39) | PTGDR2MAPTTHRBSRC | |
| SCHEMBL4312011 | 0.94 | MAPT (0.38) | PTGDR2MAPTTHRBSRCMTNR1A | |
| SCHEMBL4309650 | 0.93 | PTGDR2 (0.38) | PTGDR2MAPTTHRBSRCMTNR1A | |
| SCHEMBL4313053 | 0.92 | PTGDR2 (0.38) | PTGDR2MAPTTHRBKDM2B | |
| SCHEMBL4309221 | 0.92 | OXER1 (0.37) | PTGDR2MAPTTHRB | |
| SCHEMBL4303553 | 0.92 | PTGDR2 (0.39) | PTGDR2MAPTTHRBKDM2B | |
| SCHEMBL4314872 | 0.91 | CNR2 (0.37) | PTGDR2MAPTTHRB | |
| SCHEMBL4316778 | 0.90 | MAPT (0.38) | PTGDR2MAPTTHRBKDM2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | claimed |
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | KCNN3, KCNN1, KCNN2 | PTGDR2 482/4885MAPT 498/4885THRB 2231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.